Article(id=1236678333363179980, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236678328279683421, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1661097600000, acceptedDateStr=2022-08-22, onlineDate=1772776691046, onlineDateStr=2026-03-06, pubDate=1686758400000, pubDateStr=2023-06-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1772776691046, onlineIssueDateStr=2026-03-06, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1772776691046, creator=13701087609, updateTime=1772776691046, updator=13701087609, issue=Issue{id=1236678328279683421, tenantId=1146029695717560320, journalId=1235980733773295621, year='2023', volume='32', issue='11', pageStart='1073', pageEnd='1176', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1772776689834, creator=13701087609, updateTime=1772776816684, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1236678860406837840, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236678328279683421, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1236678860406837841, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1236678328279683421, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=1115, endPage=1120, ext={EN=ArticleExt(id=1236678335124787675, articleId=1236678333363179980, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Clinical research progress of PD-(L)1/TGF-β bispecific antibodies, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Tumor immunotherapy is a major breakthrough in the history of tumor therapy. New immunooncological drugs targeting PD-1/PD-L1 and CAR-T cells have achieved gratifying clinical efficacy. However, due to the complexity and particularity of tumor immune microenvironment, it is difficult for a single target treatment mode to achieve a lasting response. Recurrence, metastasis and resistance are still difficult for most advanced cancer patients to overcome. Recently, PD-(L)1/TGF-β bispecific antibodies have become a hot spot in the research of tumor immunomodulatory drugs, which contains two functional domains and interacts with PD-(L)1 and TGF-β simultaneously to restore the activity of T cells and enhance the immune response. This paper mainly analyzes the clinical research progress of PD-(L)1/TGF-β bifunctional antibodies, which have been developing rapidly in recent years. We further analyze the existing problems and make an outlook on the prospect of dual-target tumor immunotherapy, in order to provide basis and reference for bifunctional or multifunctional drugs.

, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Li-min ZHI, Yu LEI), CN=ArticleExt(id=1236678335351280102, articleId=1236678333363179980, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=PD-(L)1/TGF-β双特异性抗体的临床研究进展, columnId=1236330553964810454, journalTitle=中国新药杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

肿瘤免疫疗法是肿瘤治疗发展史的一项重大突破,程序性死亡受体1/程序性死亡配体1(PD-1/PD-L1)和嵌合抗原受体T细胞(CAR-T)等免疫疗法取得了令人欣喜的临床疗效,但由于肿瘤免疫微环境的复杂性和特殊性,单一靶点的治疗模式难以达到持久的应答,复发转移和耐药仍是大多数晚期癌症患者难以克服的问题。近年来,PD-(L)1/转化生长因子-β(TGF-β)双特异性抗体成为肿瘤免疫调节药物研发的一大热点,其包含2个功能结构域,能够同时与PD-(L)1和TGF-β结合,使T细胞恢复活性,增强免疫应答。本文主要分析近年发展较快的PD-(L)1/TGF-β双功能抗体的临床研究进展,并分析目前存在的问题,对双靶点肿瘤免疫治疗的前景做出展望,以期为双功能甚至多功能药物的研发和临床应用提供依据和参考。

, correspAuthors=null, authorNote=null, correspAuthorsNote=
雷宇,男,主任药师,主要从事抗肿瘤药物临床试验工作和临床药学工作。联系电话:(0771)5778582,E-mail:
, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=M/Ex573efAoaiMe+7ORTcg==, magXml=Q5BspatMql7q1I5hDPt1lg==, pdfUrl=null, pdf=rldN/cNRQzEMuA3ena6kpw==, pdfFileSize=1951177, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=HSZ2I8485FM+JBgizU9N6A==, mapNumber=null, authorCompany=null, fund=null, authors=

植丽敏,女,硕士研究生,研究方向:新药研发。E-mail:

, authorsList=植丽敏, 雷宇)}, authors=[Author(id=1236678335745544708, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1158401697@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1236678335846208009, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, authorId=1236678335745544708, language=EN, stringName=Li-min ZHI, firstName=Li-min, middleName=null, lastName=ZHI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1Guangxi Medicine University, Nanning 530021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1236678335955259918, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, authorId=1236678335745544708, language=CN, stringName=植丽敏, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1广西医科大学,南宁 530021, bio={"content":"

植丽敏,女,硕士研究生,研究方向:新药研发。E-mail:

"}, bioImg=null, bioContent=

植丽敏,女,硕士研究生,研究方向:新药研发。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1236678335531635187, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, xref=1, ext=[AuthorCompanyExt(id=1236678335540023796, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335531635187, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1Guangxi Medicine University, Nanning 530021, China), AuthorCompanyExt(id=1236678335548412405, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335531635187, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1广西医科大学,南宁 530021)])]), Author(id=1236678336043340307, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=1147112852@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1236678336123032090, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, authorId=1236678336043340307, language=EN, stringName=Yu LEI, firstName=Yu, middleName=null, lastName=LEI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1236678336211112477, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, authorId=1236678336043340307, language=CN, stringName=雷宇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2广西医科大学附属肿瘤医院,南宁 530021, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1236678335619715579, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, xref=2, ext=[AuthorCompanyExt(id=1236678335628104188, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335619715579, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, China), AuthorCompanyExt(id=1236678335644881405, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335619715579, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2广西医科大学附属肿瘤医院,南宁 530021)])])], keywords=[Keyword(id=1236678336307581476, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=EN, orderNo=1, keyword=PD-1), Keyword(id=1236678336391467559, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=EN, orderNo=2, keyword=PD-L1), Keyword(id=1236678336475353642, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=EN, orderNo=3, keyword=TGF-β), Keyword(id=1236678336567628337, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=EN, orderNo=4, keyword=bispecific antibodies), Keyword(id=1236678336655708723, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=EN, orderNo=5, keyword=immunotherapy), Keyword(id=1236678336777343543, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=CN, orderNo=1, keyword=程序性死亡受体1), Keyword(id=1236678336861229626, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=CN, orderNo=2, keyword=程序性死亡配体1), Keyword(id=1236678336966087230, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=CN, orderNo=3, keyword=转化生长因子-β), Keyword(id=1236678337075139137, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=CN, orderNo=4, keyword=双功能抗体), Keyword(id=1236678337150636613, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, language=CN, orderNo=5, keyword=免疫治疗)], refs=null, funds=null, companyList=[AuthorCompany(id=1236678335531635187, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, xref=1, ext=[AuthorCompanyExt(id=1236678335540023796, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335531635187, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1Guangxi Medicine University, Nanning 530021, China), AuthorCompanyExt(id=1236678335548412405, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335531635187, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1广西医科大学,南宁 530021)]), AuthorCompany(id=1236678335619715579, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, xref=2, ext=[AuthorCompanyExt(id=1236678335628104188, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335619715579, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, China), AuthorCompanyExt(id=1236678335644881405, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1236678333363179980, companyId=1236678335619715579, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2广西医科大学附属肿瘤医院,南宁 530021)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1772610649152, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=C, firstLetterEn=C, subjectCode=Life Sciences, subjectName=null, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1235981903275290962, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1772610649174, updatedTime=1772610649174, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1235981903338205523, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1772610649189, updatedTime=1772610649189, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=C, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2023/V32/I11/1115, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2023/V32/I11/1115, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2023/V32/I11/1115, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2023/V32/I11/1115, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)
收藏切换
PD-(L)1/TGF-β双特异性抗体的临床研究进展
收藏切换
PDF下载
植丽敏 1 , 雷宇 2
中国新药杂志 | 综述 2023,32(11): 1115-1120
收起
收藏切换
中国新药杂志 | 综述 2023, 32(11): 1115-1120
PD-(L)1/TGF-β双特异性抗体的临床研究进展
全屏
植丽敏1 , 雷宇2
作者信息
  • 1广西医科大学,南宁 530021
  • 2广西医科大学附属肿瘤医院,南宁 530021
  • 植丽敏,女,硕士研究生,研究方向:新药研发。E-mail:

通讯作者:

雷宇,男,主任药师,主要从事抗肿瘤药物临床试验工作和临床药学工作。联系电话:(0771)5778582,E-mail:
Clinical research progress of PD-(L)1/TGF-β bispecific antibodies
Li-min ZHI1 , Yu LEI2
Affiliations
  • 1Guangxi Medicine University, Nanning 530021, China
  • 2Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, China
出版时间: 2023-06-15
文章导航
收藏切换

肿瘤免疫疗法是肿瘤治疗发展史的一项重大突破,程序性死亡受体1/程序性死亡配体1(PD-1/PD-L1)和嵌合抗原受体T细胞(CAR-T)等免疫疗法取得了令人欣喜的临床疗效,但由于肿瘤免疫微环境的复杂性和特殊性,单一靶点的治疗模式难以达到持久的应答,复发转移和耐药仍是大多数晚期癌症患者难以克服的问题。近年来,PD-(L)1/转化生长因子-β(TGF-β)双特异性抗体成为肿瘤免疫调节药物研发的一大热点,其包含2个功能结构域,能够同时与PD-(L)1和TGF-β结合,使T细胞恢复活性,增强免疫应答。本文主要分析近年发展较快的PD-(L)1/TGF-β双功能抗体的临床研究进展,并分析目前存在的问题,对双靶点肿瘤免疫治疗的前景做出展望,以期为双功能甚至多功能药物的研发和临床应用提供依据和参考。

程序性死亡受体1  /  程序性死亡配体1  /  转化生长因子-β  /  双功能抗体  /  免疫治疗

Tumor immunotherapy is a major breakthrough in the history of tumor therapy. New immunooncological drugs targeting PD-1/PD-L1 and CAR-T cells have achieved gratifying clinical efficacy. However, due to the complexity and particularity of tumor immune microenvironment, it is difficult for a single target treatment mode to achieve a lasting response. Recurrence, metastasis and resistance are still difficult for most advanced cancer patients to overcome. Recently, PD-(L)1/TGF-β bispecific antibodies have become a hot spot in the research of tumor immunomodulatory drugs, which contains two functional domains and interacts with PD-(L)1 and TGF-β simultaneously to restore the activity of T cells and enhance the immune response. This paper mainly analyzes the clinical research progress of PD-(L)1/TGF-β bifunctional antibodies, which have been developing rapidly in recent years. We further analyze the existing problems and make an outlook on the prospect of dual-target tumor immunotherapy, in order to provide basis and reference for bifunctional or multifunctional drugs.

PD-1  /  PD-L1  /  TGF-β  /  bispecific antibodies  /  immunotherapy
植丽敏, 雷宇. PD-(L)1/TGF-β双特异性抗体的临床研究进展. 中国新药杂志, 2023 , 32 (11) : 1115 -1120 .
Li-min ZHI, Yu LEI. Clinical research progress of PD-(L)1/TGF-β bispecific antibodies[J]. Chinese Journal of New Drugs, 2023 , 32 (11) : 1115 -1120 .
2023年第32卷第11期
PDF下载
31
8
引用本文
BibTeX
文章信息
  • 首发时间:2026-03-06
  • 出版时间:2023-06-15
补充材料
相关文章
文章信息
作者
出版历史
  • 录用日期:2022-08-22
基金
作者信息
    1广西医科大学,南宁 530021
    2广西医科大学附属肿瘤医院,南宁 530021

通讯作者:

雷宇,男,主任药师,主要从事抗肿瘤药物临床试验工作和临床药学工作。联系电话:(0771)5778582,E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1236678333363179980
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏